173 related articles for article (PubMed ID: 35831273)
1. Aurora-A/FOXO3A/SKP2 axis promotes tumor progression in clear cell renal cell carcinoma and dual-targeting Aurora-A/SKP2 shows synthetic lethality.
Li P; Chen T; Kuang P; Liu F; Li Z; Liu F; Wang Y; Zhang W; Cai X
Cell Death Dis; 2022 Jul; 13(7):606. PubMed ID: 35831273
[TBL] [Abstract][Full Text] [Related]
2. Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality.
Zhang W; Xia D; Li Z; Zhou T; Chen T; Wu Z; Zhou W; Li Z; Li L; Xu J
Cell Death Dis; 2019 Aug; 10(8):606. PubMed ID: 31406104
[TBL] [Abstract][Full Text] [Related]
3. Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma.
Chen T; Liu L; Zou Y; Hu X; Zhang W; Zhou T; Luo X; Fu W; Xu J
Cancer Biol Med; 2021 Feb; 18(1):227-244. PubMed ID: 33628597
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Akt/FoxO3a/Skp2 Axis Is Critically Involved in Berberine-Induced Cell Cycle Arrest in Hepatocellular Carcinoma Cells.
Li F; Dong X; Lin P; Jiang J
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29360760
[TBL] [Abstract][Full Text] [Related]
5. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells.
Ding XF; Zhou J; Chen G; Wu YL
Mol Med Rep; 2018 Jul; 18(1):1206-1210. PubMed ID: 29845253
[TBL] [Abstract][Full Text] [Related]
6. EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt/FOXO3a pathway.
Zhou X; Dong S; Zhou Y; He Z; Zhang Z; Liao L; Zou B; Zheng X; Peng K; Duan X
Mol Carcinog; 2024 May; 63(5):951-961. PubMed ID: 38362840
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma.
Ni D; Ma X; Li HZ; Gao Y; Li XT; Zhang Y; Ai Q; Zhang P; Song EL; Huang QB; Fan Y; Zhang X
Clin Cancer Res; 2014 Apr; 20(7):1779-90. PubMed ID: 24486593
[TBL] [Abstract][Full Text] [Related]
8. Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC).
Martin B; Chesnel F; Delcros JG; Jouan F; Couturier A; Dugay F; Le Goff X; Patard JJ; Fergelot P; Vigneau C; Rioux-Leclerq N; Arlot-Bonnemains Y
PLoS One; 2013; 8(6):e67071. PubMed ID: 23785518
[TBL] [Abstract][Full Text] [Related]
9. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
10. The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma.
Lu M; Ma J; Xue W; Cheng C; Wang Y; Zhao Y; Ke Q; Liu H; Liu Y; Li P; Cui X; He S; Shen A
Pathol Oncol Res; 2009 Dec; 15(4):679-87. PubMed ID: 19404778
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
12. A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma.
Zhai W; Zhu R; Ma J; Gong D; Zhang H; Zhang J; Chen Y; Huang Y; Zheng J; Xue W
Mol Cancer; 2019 Apr; 18(1):81. PubMed ID: 30953521
[TBL] [Abstract][Full Text] [Related]
13. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in Clear Cell Renal Carcinoma.
Chen SL; Huang QS; Huang YH; Yang X; Yang MM; He YF; Cao Y; Guan XY; Yun JP
Theranostics; 2020; 10(20):9186-9199. PubMed ID: 32802186
[TBL] [Abstract][Full Text] [Related]
14. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS
Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249
[TBL] [Abstract][Full Text] [Related]
15. Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.
Zhang Y; Ma Y; Wang Y; Mukhopadhyay D; Bi Y; Ji B
Pancreatology; 2022 Jun; 22(5):619-625. PubMed ID: 35550115
[TBL] [Abstract][Full Text] [Related]
16. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
17. Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways.
Lu H; Cao X; Zhang H; Sun G; Fan G; Chen L; Wang S
Tumour Biol; 2014 Oct; 35(10):9807-13. PubMed ID: 24986570
[TBL] [Abstract][Full Text] [Related]
18. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
19. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
20. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma.
Kuang Z; Guo K; Cao Y; Jiang M; Wang C; Wu Q; Hu G; Ao M; Huang M; Qin J; Zhao T; Lu S; Sun C; Li M; Wu T; Liu W; Fang M
Br J Cancer; 2023 Dec; 129(12):1915-1929. PubMed ID: 37884683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
